Back Pain Doctor

PRP for Sacroiliac Joint Pain: The Evidence

Platelet-rich plasma at the sacroiliac joint is one of the clearest examples in musculoskeletal medicine of why trial quality has to be read before trial conclusions. There are two randomised comparisons against corticosteroid. One strongly favours PRP. The other, which was double-blinded and used stricter patient selection, favours corticosteroid. Anyone presenting this treatment as established is not reading both.

Where the guidelines land

The 2025 multispecialty consensus guidelines, endorsed by 21 organisations with complete committee consensus, state that there is weak evidence supporting dextrose-based prolotherapy and platelet-rich plasma to provide at least three months of pain relief in sacroiliac joint complex pain.

That is a real position — it is not nothing, and it is not an endorsement. 'Weak evidence for at least three months of relief' is the whole claim, and it is the claim made here.

The 2019 ASIPP biologics guidelines reached the same neighbourhood independently, grading sacroiliac joint PRP as Level IV evidence on a scale of I to V, based on one high-quality randomised trial, one moderate-quality observational study and one low-quality case report.

The two randomised trials, side by side

Singla 2017 Chen 2022
JournalPain PracticePain Medicine
DesignProspective randomised open blinded endpoint (PROBE) — participants and injector not blindedDouble-blind randomised controlled trial
SettingSingle centreTwo large university spine centres
n4026
GuidanceUltrasoundFluoroscopy
SelectionChronic low back pain diagnosed with SIJ pathologyPositive diagnostic block required, with more than 80 per cent relief
ComparatorMethylprednisolone 40 mg/mL with lidocaineIntra-articular corticosteroid
Follow-up2, 4 and 6 weeks and 3 months1, 3 and 6 months
ResultPRP significantly better. Median VAS at 3 months 1 (IQR 1-3) with PRP versus 5 (IQR 3-5) with steroid, p=0.0002. Efficacy at 3 months 90 per cent with PRP versus 25 per cent with steroid.Corticosteroid significantly better. Both groups improved, but steroid patients reported lower pain at 1, 3 and 6 months and there were significantly more responders (≥50 per cent improvement) in the steroid group at 1 and 3 months.

How to weigh two trials that disagree

  • Chen's trial was double-blinded. Singla's was not — participants and the injecting clinician knew which treatment was given, which is a substantial source of bias in a pain outcome.
  • Chen's trial required more than 80 per cent relief from a diagnostic block before enrolment, so it studied a population in which the sacroiliac joint was genuinely the pain source. Singla's entry criteria were looser.
  • Chen's trial was smaller (26 versus 40) and multicentre; Singla's was larger and single-centre.
  • The trials also used different guidance — ultrasound in the positive one, fluoroscopy in the negative one. That is worth noting rather than leaning on: the only randomised comparison of the two modalities at this joint found no difference in outcome, so guidance is unlikely to be the explanation for the disagreement.
  • On design grounds the negative trial is the stronger of the two. That does not make PRP useless — it means the confident positive claims made for it do not survive the better trial.

What the systematic reviews conclude

Review What it included Conclusion
Burnham 2020, Pain Medicine151 publications screened, 3 eligible PRP studies (1 RCT, 2 case series). No eligible bone marrow aspirate studies.Evidence rated very low quality by GRADE. Pooled pain outcomes showed 28 of 30 patients (93 per cent) achieved at least 50 per cent pain improvement at 3 months — but from two studies only. The single RCT's adjusted odds ratio was 37, with a 95 per cent confidence interval of 4.65 to 298.69, which is the statistical signature of a very small study.
Manchikanti 2025, Current Pain and Headache Reports2 RCTs and 3 observational studies meeting quality criteriaGRADE evidence level IV (limited), weak recommendation.
Goodwin 2023, Regenerative Medicine259 articles retrieved, 4 clinical trials and 2 case studies appraisedNot enough evidence to support PRP over the current corticosteroid standard of care. Further double-blind randomised trials required.
Rothenberg 2021, Regenerative Medicine7 studies of PRP into the SIJ or its ligamentsAll 7 improved on their primary endpoint with a strong safety profile and no serious adverse events, but only 5 demonstrated clinical efficacy above 50 per cent. Inconsistent and insufficient evidence for a conclusive recommendation either for or against.

Note the consistency across four independent reviews with different inclusion criteria: none of them concludes that PRP is established at this joint, and none concludes that it is useless. The uncertainty is genuine rather than rhetorical.

The gap nobody discusses: joint versus ligament

Both randomised trials injected inside the joint. The 2025 guidelines concluded that intra-articular and extra-articular pathology are about equally common in this condition — which means roughly half the relevant patient population has not been studied in a randomised trial of PRP at all.

Rothenberg's review is the one that looked at PRP into the SIJ or its ligaments, and it found only seven studies in total across both targets, five of which reached the 50 per cent efficacy mark.

So the honest position on posterior ligament PRP specifically is that it is a reasonable extension of the intra-articular evidence and the anatomy, and that it has not been tested against a control in its own right. That is said plainly at the point of consent here rather than left as an impression.

What can be said for the target is that it is the one ultrasound reaches best, and the one the guidelines found the corticosteroid evidence slightly stronger for. That is an argument about which structure to treat, not evidence that PRP treats it.

Safety

The safety record across this literature is good. No serious adverse events were reported in any of the seven studies in Rothenberg's review, none in Singla's trial, and none in the comparative platelet-rich fibrin study of 186 patients by Mohi Eldin and colleagues.

The usual risks of any injection apply: bleeding, infection, a temporary increase in pain in the days afterward, and vasovagal reaction. PRP is autologous, so there is no risk of a reaction to a foreign protein, but the blood draw and processing add their own small risks.

Post-injection soreness for several days is expected rather than a complication, and the loading programme is adjusted around it rather than abandoned.

How this is used here

The conditions under which PRP is offered for SIJ pain

  • After the diagnosis has been characterised properly, including which part of the complex is suspected — because that determines the target. Injections are given under ultrasound guidance, which suits the posterior ligamentous structures well; where the intended target cannot be reached safely or reliably that way, the injection is referred to a radiologist to perform under CT guidance rather than approximated here.
  • After an adequately delivered rehabilitation programme. Three months of supervised, progressive loading is the reference point, taken from the Sydney protocol.
  • As something that may open a window in which the loading work becomes possible, not as a repair of the joint or a tightening of the ligaments.
  • With the Chen trial stated explicitly in the consent conversation, not omitted. The comparison that matters for most people is against repeated corticosteroid, and one good trial found corticosteroid did better.
  • With costs, out-of-pocket expense and the absence of a Medicare rebate for the injectable itself set out before you decide. See the fees page.
  • Not as a first-line treatment, and not as a series booked in advance before the response to the first is known.

Related on this site

Common questions

Does PRP work for sacroiliac joint pain?
The honest answer is that it is uncertain, and that the two randomised trials disagree. An open-label trial of 40 patients found PRP clearly better than corticosteroid at three months. A double-blind trial of 26 patients, using fluoroscopic guidance and requiring more than 80 per cent relief from a diagnostic block before enrolment, found corticosteroid better at one, three and six months. Four systematic reviews have each concluded the evidence is too limited to recommend for or against it. The 2025 multispecialty consensus guidelines describe the evidence as weak, supporting at least three months of relief.
Is PRP better than a cortisone injection for the SIJ?
Not established, and one well-designed trial found the opposite. The double-blind trial by Chen and colleagues found that corticosteroid produced lower pain scores at one, three and six months and significantly more responders at one and three months. The open-label trial by Singla and colleagues found the reverse. The difference in blinding and patient selection between the two is the reason they are weighted differently here.
Has PRP into the SIJ ligaments been tested?
Not in a randomised controlled trial. Both randomised trials injected inside the joint. The one review that looked at PRP into the joint or its ligaments found seven studies in total across both targets. Since ligamentous and intra-articular pain appear to be about equally common, this is a real gap in the evidence and it is stated rather than glossed over.
How many PRP injections would I need?
There is no established protocol at this joint — the studies used different preparations, volumes and schedules, which is one of the reasons the reviews rate the evidence as very low quality. What is done here is a single injection first, with the decision about any further injection made on the measured response rather than booked in advance.
Is PRP safe?
The safety record in this literature is good. No serious adverse events were reported across the seven studies in Rothenberg's review, in Singla's randomised trial, or in a comparative study of 186 patients. The ordinary risks of injection apply — bleeding, infection, temporary increased pain and vasovagal reaction — and several days of post-injection soreness is expected rather than a complication.
Is PRP covered by Medicare?
The preparation and injection of PRP itself does not attract a Medicare rebate in Australia. The consultation in which it is discussed is a normal GP attendance. Costs are set out before any decision is made — see the fees page.

Evidence reviewed

Every clinical statement on this page traces to one of the sources below, including the ones that point the other way. Where a study is small, unblinded or authored by people with a commercial interest in the result, that is noted alongside it rather than left out.

Last reviewed 2026-09-04. This is general information about a condition and its treatments, not personal medical advice, and it is no substitute for assessment by a clinician who has examined you.

More in this section

The joint and its ligaments

Why the ligaments behind the joint matter as much as the joint itself — and why that changes where a needle goes.

Lumbopelvic instability

A useful clinical model that has been badly oversold. Here is the part that holds up.

Getting the diagnosis right

No single test proves it. Here is what each one is actually worth.

The rehabilitation programme

Twenty weeks, four phases, with the criteria for moving between them — and the reason unsupervised versions of this fail.

Protocols for clinicians

Written for referrers and physiotherapists: the parameters, the outcome measures and the effect sizes, without the patient framing.

Prolotherapy at the sacroiliac joint

The longest trial record at this joint — and a real-world cohort where fewer than a quarter of patients improved.

Shockwave and EMTT

Two small randomised trials, one sham-controlled, and a device with no trials at all.

Referral, ablation and surgery

The procedures not done here, what their evidence actually shows, and when a referral is the right answer.

Ready for a clearer plan for your back or musculoskeletal pain?

Book an assessment with Dr Joshua Hatch.

Your assessment focuses on understanding the likely source of your pain and the most appropriate non-surgical options for your diagnosis, with the aim of reducing pain and improving function.

Book an appointment
Book an appointment with Back Pain Doctor
Book now Call